CD38 Monoclonal Antibody Therapies for Multiple Myeloma

Sandy W Wong; Raymond L Comenzo

doi:10.1016/j.clml.2015.07.642

CD38 Monoclonal Antibody Therapies for Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):635-45. doi: 10.1016/j.clml.2015.07.642. Epub 2015 Aug 5.

Authors

Sandy W Wong¹, Raymond L Comenzo²

Affiliations

¹ Departments of Medicine and Pathology and the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA. Electronic address: Swong7@tuftsmedicalcenter.org.
² Departments of Medicine and Pathology and the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA.

PMID: 26443328
DOI: 10.1016/j.clml.2015.07.642

Abstract

The goal of this review is to provide historical, recent preclinical, and current clinical summaries of efforts to understand the CD38 molecule and to develop monoclonal antibodies that target it. We focus particularly on efforts involving multiple myeloma, a malignancy of terminally differentiated B cells that remains incurable despite many advances. An era of anti-CD38 monoclonal antibody therapy for myeloma is approaching, one that, we hope, will enable patients to live longer and better lives.

Keywords: Anti-CD38; CD38; Immunotherapy; Monoclonal antibody; Multiple myeloma.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
ADP-ribosyl Cyclase 1 / chemistry
ADP-ribosyl Cyclase 1 / genetics
ADP-ribosyl Cyclase 1 / metabolism
Animals
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Drug Discovery
Drug Evaluation, Preclinical
Humans
Molecular Targeted Therapy
Multiple Myeloma / drug therapy*
Multiple Myeloma / etiology
Multiple Myeloma / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
ADP-ribosyl Cyclase 1